⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LTRN News
Lantern Pharma Inc. Common Stock
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
businesswire.com
LTRN
Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™
businesswire.com
LTRN
Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally
businesswire.com
LTRN
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global
accessnewswire.com
NRXP
MDCX
IGC
RDZN
LTRN
CISO
Join Lantern Pharma on April 30 for the First Public Demonstration of with Zeta.ai - A Platform to Conquer Rare Cancers
accessnewswire.com
LTRN
Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut
businesswire.com
LTRN
CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers
accessnewswire.com
LTRN
Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity
businesswire.com
LTRN
RedChip's Biotech Investor Conference Replays Now Available
accessnewswire.com
SXTP
BIVI
BFRG
LTRN
NXL
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
businesswire.com
LTRN